“
TL;DR
This action reduces PD-L1 expression in the tumor microenvironment, leading to decreased tumor growth and potentially improved anti-tumor immunity.
Cancer Science · 13 authors, 2 centres
This summary was generated by AI from a single paper. It has not been reviewed by a clinician and is not clinical advice. Verify against the source before acting on it.
This action reduces PD-L1 expression in the tumor microenvironment, leading to decreased tumor growth and potentially improved anti-tumor immunity.
This preclinical study investigates the mechanism by which obesity may impair immune response in triple-negative breast cancer (TNBC). Using an obese mouse model, the authors demonstrate that high leptin levels from adipocytes promote tumor cell PD-L1 expression, leading to T-cell exhaustion and immunosuppression. They show that baicalein treatment in these mice inhibited adipocyte leptin secretion by downregulating the transcription factor SREBP1. This resulted in reduced tumor PD-L1 expression and suppressed tumor growth. The study is limited by its preclinical, animal and cell-line model design. The findings suggest baicalein may have therapeutic potential to enhance anti-tumor immunity in obese TNBC patients by targeting the adipocyte-leptin-PD-L1 axis.